Who are Eli Lilly's decision-makers?

David A. Ricks has served as Chairman and CEO since 2017, steering Lilly through its transformation from a diversified mid-size pharma into a GLP-1-powered global leader. Named Chief Executive Magazine's 2025 CEO of the Year, Ricks championed both the commercial tirzepatide franchise and the LillyDirect direct-to-patient platform that disrupts traditional PBM distribution. His prior roles at Lilly include President of BioMedicines (which oversaw insulin and immunology) and President of Lilly USA, giving him deep insight into both the R&D and commercial sides of the business.

Daniel Skovronsky, MD, PhD (Chief Scientific and Product Officer) is the architect of Lilly's R&D engine. He joined via the 2010 acquisition of Avid Radiopharmaceuticals, which he co-founded in 2004, and now oversees all clinical development — including the tirzepatide franchise, retatrutide, donanemab, and orforglipron — plus commercial responsibility for major product franchises. Lucas Montarce (CFO) joined Lilly in 2001 and has served in multiple finance leadership roles, including global CFO of Elanco Animal Health (Lilly's animal health spinoff, separately listed) and CFO of Lilly Research Laboratories. Diogo Rau (Chief Information and Digital Officer) previously served as Apple's VP of Information Systems before joining Lilly in 2021 to lead its cloud modernization and AI-infrastructure push.

At a company of Lilly's scale, buying authority is distributed by function and deal size. For enterprise software and cloud infrastructure, the key decision-maker is Diogo Rau (EVP, Chief Information and Digital Officer), with technical input from Timothy Coleman (SVP, Chief Technology Officer) and budget governed through Lucas Montarce's (CFO) office. Deals above approximately $10M typically route through the Executive Committee; major infrastructure decisions (ERP, cloud, data platforms) require CFO and CEO alignment.

For R&D and clinical trial services, Daniel Skovronsky's organization (President, Lilly Research Laboratories) controls CRO/CDMO vendor selection, data platform procurement, and AI/analytics tools for drug discovery. Edgardo Hernandez (EVP, Manufacturing Operations) owns manufacturing IT, supply chain platforms, and automation vendors. For commercial and marketing technology, Ilya Yuffa (EVP, President Lilly USA and Global Customer Capabilities) manages CRM strategy and HCP engagement tools — Lilly is a confirmed Salesforce and Veeva CRM customer. Thomas J. Fuchs, appointed as Lilly's first Chief AI Officer in October 2024, oversees AI strategy across all divisions and is an increasingly important stakeholder for AI/ML vendor decisions.

Lilly restructured its commercial organization in 2024–2025 to accelerate divisional accountability. The company now operates through four therapeutic divisions — Cardiometabolic Health (Kenneth Custer, EVP), Oncology (Jacob Van Naarden, EVP), Immunology (Adrienne Brown), and Neuroscience (Carole Ho) — each with P&L accountability and independent commercial leadership. This divisional model means each unit can independently procure specialized vendors (e.g., oncology-specific data analytics, immunology patient support tools) within budgets delegated by the CFO.

Global operations are divided between Lilly USA (Ilya Yuffa) and Lilly International (Patrik Jonsson), with Manufacturing reporting separately under Edgardo Hernandez. Corporate Business Development (also under Jacob Van Naarden) runs all M&A, partnerships, and licensing — the group that executed $4B+ in 39 transactions in 2025. The result is a matrix organization where functional buyers (IT, Finance, Legal) interact with divisional buyers (Cardiometabolic, Oncology) for most major vendor decisions. Sales cycles to Lilly typically run 12–24 months for enterprise software, with procurement and legal reviews adding additional time at contract stage.